Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

On 8 September 2024, Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific monoclonal antibody that binds to vascular ...

First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median ...

The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...

Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...

Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination ...